ARCTEarnings•businesswire•
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
Sentiment:Positive (65)
Summary
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates. “The Company continues to advance and provide meaningful clinical data across our mRNA therapeutics and vaccines pipeline,
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by businesswire